Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Valérie Gounant, Valentine Marie Ferré, Ghassen Soussi, Charlotte Charpentier, Héloïse Flament, Nadhira Fidouh, Gilles Collin, Céline Namour, Sandra Assoun, Alexandra Bizot, Zohra Brouk, Eric Vicaut, Luis Teixeira, Diane Descamps, View ORCID ProfileGérard Zalcman
doi: https://doi.org/10.1101/2021.08.12.21261806
Valérie Gounant
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MD, MSc.Valentine Marie Ferré
3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
PharmD, MSc.Ghassen Soussi
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MDCharlotte Charpentier
3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
PharmD, PhDHéloïse Flament
4Université de Paris, Hematology and Immunology Department, INSERM-U1149, Research Center on Inflammation (CRI) Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
PharmD, PhDNadhira Fidouh
3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
PharmDGilles Collin
3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
Msc.Céline Namour
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MSc.Sandra Assoun
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MD, MscAlexandra Bizot
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MD, MSc.Zohra Brouk
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
PhDEric Vicaut
5Université de Paris, Biostatistics and Clinical Research Department, Lariboisière Hospital (AP-HP.Nord), 2 rue Amboise Paré, 75018 Paris, France
MD, PhDLuis Teixeira
6Université de Paris, North-Paris Cancer University Institute, Breast Diseases Centre, INSERM U976, HIPI, “Pathophysiology of Breast Cancer Team”, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 1 avenue Claude Vellefaux, 75010 Paris, France
MD, PhDDiane Descamps
3Université de Paris, Virology Department, INSERM UMR1137 “Infection, Antimicrobials, Modelling, Evolution”, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
MD, PhDGérard Zalcman
1Université de Paris, North-Paris Cancer University Institute, Thoracic Oncology Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
2INSERM Centre d’Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), 46 rue Henri Huchard, Paris, France
7INSERM U830 “Cancer, Heterogeneity Plasticity”, Curie Institute Research Centre, 26 rue d’Ulm, 75231 Paris cedex 05, France
MD, PhDData Availability
All the data are available on request to the senior authoor of the article, Prof. Gerard ZALCMAN gerard.zalcman{at}aphp.fr
Posted August 13, 2021.
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Valérie Gounant, Valentine Marie Ferré, Ghassen Soussi, Charlotte Charpentier, Héloïse Flament, Nadhira Fidouh, Gilles Collin, Céline Namour, Sandra Assoun, Alexandra Bizot, Zohra Brouk, Eric Vicaut, Luis Teixeira, Diane Descamps, Gérard Zalcman
medRxiv 2021.08.12.21261806; doi: https://doi.org/10.1101/2021.08.12.21261806
Efficacy of SARS-CoV-2 vaccine in thoracic cancer patients: a prospective study supporting a third dose in patients with minimal serologic response after two vaccine doses
Valérie Gounant, Valentine Marie Ferré, Ghassen Soussi, Charlotte Charpentier, Héloïse Flament, Nadhira Fidouh, Gilles Collin, Céline Namour, Sandra Assoun, Alexandra Bizot, Zohra Brouk, Eric Vicaut, Luis Teixeira, Diane Descamps, Gérard Zalcman
medRxiv 2021.08.12.21261806; doi: https://doi.org/10.1101/2021.08.12.21261806
Subject Area
Subject Areas
- Addiction Medicine (383)
- Allergy and Immunology (699)
- Anesthesia (192)
- Cardiovascular Medicine (2853)
- Dermatology (244)
- Emergency Medicine (430)
- Epidemiology (12561)
- Forensic Medicine (10)
- Gastroenterology (806)
- Genetic and Genomic Medicine (4434)
- Geriatric Medicine (402)
- Health Economics (716)
- Health Informatics (2850)
- Health Policy (1049)
- Hematology (375)
- HIV/AIDS (893)
- Medical Education (413)
- Medical Ethics (114)
- Nephrology (462)
- Neurology (4194)
- Nursing (222)
- Nutrition (617)
- Oncology (2204)
- Ophthalmology (624)
- Orthopedics (254)
- Otolaryngology (318)
- Pain Medicine (268)
- Palliative Medicine (82)
- Pathology (486)
- Pediatrics (1172)
- Primary Care Research (483)
- Public and Global Health (6783)
- Radiology and Imaging (1490)
- Respiratory Medicine (900)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (202)
- Urology (174)